Evidence map›Paper›PMID 30413667›Full record

Observational studyThe oncologist2019

Eribulin Mesylate as Third or Subsequent Line Chemotherapy for Elderly Patients with Locally Recurrent or Metastatic Breast Cancer: A Multicentric Observational Study of GIOGer (Italian Group of Geriatric Oncology)-ERIBE.

Silvana Leo, Ermenegildo Arnoldi, Lazzaro Repetto, Zaira Coccorullo, Saverio Cinieri, Palma Fedele, Marina Cazzaniga, Vito Lorusso, Agnese Latorre, Giovanna Campanella and 11 more

Registry-linked trialOpen access · bronzeAbstract readMulticenter StudyObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in The oncologist, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06471673 (A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer), which is not on this map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06471673 phase1 / phase2recruitingnot on this mapstarted 2024, after this paper: background citation

A Study of BRIA-OTS Cellular Immunotherapy in Metastatic Recurrent Breast Cancer

TypeinterventionalSponsorBriaCell Therapeutics CorporationRan2024 to 2025Enrolled18ConditionsBreast Cancer, Breast Tumor, Cancer of Breast, Cancer of the BreastArmsBC1 cell line, Bria-OTS regimen and CPI (tislelizumab), Bria-OTS regimen and CPI (tislelizumab) expansion cohort
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 21 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 11 institutions in 1 country.

Silvana LeoOspedale Fazzi, Lecce, Italy silvileo59@gmail.com.
Ermenegildo ArnoldiOspedali Riuniti di Bergamo, Bergamo, Italy.
Lazzaro RepettoOspedale Civile Borea, Sanremo, (IM), Italy.
Zaira CoccorulloOspedale Civile Borea, Sanremo, (IM), Italy.
Saverio CinieriOspedale Perrino, Brindisi, Italy.
Palma FedeleOspedale Perrino, Brindisi, Italy.
Marina CazzanigaOspedale San Gerardo, Monza, Italy.
Vito LorussoIstituto Tumori Giovanni Paolo II, Bari, Italy.
Agnese LatorreIstituto Tumori Giovanni Paolo II, Bari, Italy.
Giovanna CampanellaIRCCS Ospedale De Bellis, Castellana Grotte, (BA), Italy.
Mariangela CiccareseOspedale Fazzi, Lecce, Italy.
Caterina AccetturaOspedale Fazzi, Lecce, Italy.
Salvatore PiscontiOspedale San Giuseppe Moscati, Taranto, Italy.
Antonio RinaldiOspedale Civile, Castellaneta, (TA), Italy.
Cosimo BrunettiOspedale Civile, Manduria, (TA), Italy.
Mimma RaffaelePresidio Ospedaliero Sant'Andrea-San Filippo Neri, Rome, Italy.
Luigi ColtelliOspedale Lotti Azienda USL 5, Pontedera (PI), Italy.
Salvatore SpazzapanCRO, Aviano, (PN), Italy.
Lucia FratinoCRO, Aviano, (PN), Italy.
Luciana PetrucelliOspedale Fazzi, Lecce, Italy.
Laura BiganzoliNuovo Ospedale di Prato, Prato, Italy.
Ospedale Vito Fazzi · ITCentro di Riferimento Oncologico · ITIstituto Tumori Bari · ITOspedale A. Perrino · ITAzienda Ospedaliera San Gerardo · ITGastroenterology Hospital "Saverio de Bellis" · ITLega Italiana per la Lotta ai Tumori · ITNuovo Ospedale di Prato · ITOspedale San Giuseppe · ITPresidio Ospedaliero · ITUniversity of Bergamo · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundMetastatic breast cancer (MBC) is highly prevalent in middle-aged or elderly patients. Eribulin is a nontaxane microtubule inhibitor, approved for the treatment of pretreated MBC. This multicentric study (sponsored by GIOGer, Italian Group for Geriatric Oncology) was designed to assess the efficacy and tolerability of eribulin, according to parameters usually used in geriatric oncology. SUBJECTS, MATERIALS, AND

methodsAn observational study was conducted on 50 consecutive elderly patients with MBC. The primary endpoint was to evaluate the change in items score of comprehensive geriatric assessment (CGA) and health-related quality of life (HRQL). Italian versions of the CGA and HRQL questionnaires were administered at baseline, before the third and fifth cycles, and then every three cycles until treatment discontinuation. Secondary endpoints were efficacy and safety.

resultsOverall, both EQ-5D scores and EQ-5D-3 L visual analogic scale did not significantly change from baseline; the percentage of subjects without problems doing usual activities tended to decrease during treatment (

conclusionEribulin treatment preserved quality of life and geriatric parameters included in the CGA, except for instrumental functioning and geriatric depression, in elderly patients with MBC. IMPLICATIONS FOR PRACTICE: A collaboration between oncologist and geriatric specialists is essential in the management of patients with metastatic breast cancer, who are frequently elderly or frail. The assessment of geriatric parameters in the decision-making process can contribute to direct toward the most appropriate therapeutic plan and preserve the quality of life of patients. Eribulin does not seem to affect quality of life or worsen the overall geriatric status; therefore, it can be considered a suitable option for elderly patients with metastatic breast cancer.

Indexed as

Activities of Daily LivingAgedAged, 80 and overAntineoplastic AgentsBreast NeoplasmsFemaleFollow-Up StudiesFuransGeriatric AssessmentHumansItalyKetonesNeoplasm Recurrence, LocalPolyether PolyketidesProspective StudiesQuality of LifeAntineoplastic AgentseribulinFuransKetonesPolyether PolyketidesTubulin ModulatorsComprehensive geriatric assessmentElderlyEribulin mesylateHealth‐related quality of lifeMetastatic breast cancer

Identifiers

PMID30413667
PMCPMC6656485
OpenAlexW2899527071

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.